Journals / The Journal of Pediatric Research / 2017 / Cilt: 4 - Sayı: 3

The Effect of Vagal Nerve Stimulation on the Quality of Life in Pediatric Cases

Çoçuk Hastalarda Vagus Sinir Uyarımının Yaşam Kalitesi Üzerine Etkileri

Pages
137–142
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We think that the scores of depression inventory should gradually decrease in years as it is reported for seizure frequency.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To evaluate the value of vagal nerve stimulation (VNS) in improving the quality of life, seizure frequency and mood in children with pharmacoresistant epilepsy.
📊
Key Findings & Data:Materials and Methods: Eleven pharmacoresistant epileptic children implanted with the VNS therapy device between 2010-2014 were included in this prospective longitudinal study.
💡
Conclusion & Impact:We think that the scores of depression inventory should gradually decrease in years as it is reported for seizure frequency.
🔬Design:Research Article
📍Scope:2010-2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: To evaluate the value of vagal nerve stimulation (VNS) in improving the quality of life, seizure frequency and mood in children with pharmacoresistant epilepsy. Materials and Methods: Eleven pharmacoresistant epileptic children implanted with the VNS therapy device between 2010-2014 were included in this prospective longitudinal study. Clinical assessment for the Diagnostic and Statistical Manual of Mental Disorders-IV psychiatric disorders, schedule for affective disorders, and schizophrenia for school children were applied. Childhood Depression Inventory (CDI), Beck Depression Inventory (BDI) were filled. Child Behavior Checklist (CBCL) and the Pediatric Quality of Life Inventory (PedsQL) were filled in by parents before the implantation. All of these tests were repeated in the first and second year of implantation.Results: Mean age at the first implantation of the VNS therapy device was 11.5 . Mean age was 13.9 years. Mean duration of epilepsy prior to VNS implantation was 6.6 years, and VNS usage period was 30.4 months . International League Against Epilepsy classification of predominant seizure type was partial in seven, and generalized in four patients. Decrease in the number of seizures was 42% and 43% in the first and the second year respectively. While four of 11 patients had no psychopathology, different problems were determined in seven patients. There was no statistically significant difference between the scores of CDI/BDI, scores of CBCL and PedsQL prior to implantation, and also did not differ 1 year and 2 years after implantation.Conclusion: VNS is partially effective in controlling drug-resistant epilepsy. Although a positive effect on depression and quality of life is reported in literature, the results of this study were not statistically significant. We think that the scores of depression inventory should gradually decrease in years as it is reported for seizure frequency.

Özet

Amaç: Dirençli epilepsi hastalarında vagal sinir uyarımı (VSU) sonrası yaşam kalitesi, nöbet sıklığı ve psikiyatrik değerlendirilmesini değerlendirmeyi amaçladık.Gereç ve Yöntemler: 2010-2014 yılları arasında VSU uygulanan 11 dirençli epilepsi hastası tek merkezli longitudinal gözlemsel prospektif çalışmaya alınmıştır. Hastalar VSU tedavisi öncesi, nöbet sıklığı, Ruhsal Bozuklukların Tanısal ve Sayımsal El Kitabı-IV psikiyatrik bozuklukları için yarı yapılandırılmış klinik görüşme Okul Çağı Çocukları için Duygulanım Bozuklukları ve Şizofreni Görüşme Çizelgesi-Şimdi ve Yaşam Boyu Şekli ile değerlendirilmiş ve Çocuklar için Depresyon Ölçeği (ÇDÖ), Beck Depresyon Envanteri (BDE), Çocuklar için Durumluk ve Sürekli Kaygı Ölçeği ve Hastalık Algısı Ölçeği doldurmuştur. Aileleri ise Çocuk ve Gençlerde Davranış Değerlendirme Ölçeği (ÇDDÖ) ve Çocuklar için Yaşam Kalitesi Ölçeği (ÇİYKÖ)-ebeveyn formu doldurmuştur. Tüm değerlendirmeler VSU uygulamasından önce, 1. yılında ve 2. yılında tekrarlanmıştır. Bulgular: VSU takılma yaşı ortalama 11,5 yaş idi. Yaş ortalaması 13,9 yaş idi. Hastaların VSU öncesi epilepsi nedeniyle izlem süresi ortalama 6,6 yıl, VSU kullanım süresi ortalama 30,4 aydır. Uluslararası Epilepsi ile Savaş Derneği sınıflamasına göre yedi hasta fokal epilepsi, dört hasta jeneralize epilepsi idi. Hastaların VSU ile izlemlerinin ilk yılında nöbet sıklığında ortalama %42, ikinci yıl %43 azalma saptandı. Hastaların ilk vizitlerinde dördünde psikopatoloji bulunmazken yedi hastada değişik psikopatolojiler tanımlanmıştır. Hastaların ÇDÖ/BDE, ÇİYKÖ, ÇDDÖ değerlendirilmelerinde VSU uygulaması öncesi, 1. yıl ve 2. yıl arasında fark saptanmadı.Sonuç: İlaca dirençli epilepsilerde VSU faydalıdır. Literatürde depresyon ve yaşam kalitesine faydalı olduğu gösterildiği halde çalışmamızda anlamlı bir fark saptanmadı. Nöbet sıklığında olduğu gibi ilerleyen yıllarda depresyon ölçeklerinde de iyileşme olacağını düşünmekteyiz.

🔖

Cite This Article

TEKİN, H. G., KÖSE, S., GÖKBEN, S., ERERMİŞ, H. S., TURHAN, T., TEKGÜL, H., YILMAZ, S. K., SERDAROĞLU, G. (2017). The Effect of Vagal Nerve Stimulation on the Quality of Life in Pediatric Cases. The Journal of Pediatric Research, Cilt: 4 - Sayı: 3, 137–142. https://ajindex.com/articles/362814

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Healy S, Lang J, Te Water Naude J, Gibbon F, Leach P. Vagal nerve stimulation in children under 12 years old with medically intractable epilepsy. Childs Nerv Syst 2013;29:2095-9
  2. Ryzí M, Brázdil M, Novák Z, et al Long-term vagus nerve stimulation in children with focal epilepsy. Acta Neurol Scand 2013;127:316-22
  3. Klinkenberg S, van den Bosch CN, Majoie HJ, et al. Behavioural and cognitive effects during vagus nerve stimulation in children with intractable epilepsy - a randomized controlled trial. Eur J Paediatr Neurol 2013;17:82-90
  4. Cersósimo RO, Bartuluchi M, Fortini S, Soraru A, Pomata H, Caraballo RH. Vagus nerve stimulation: effectiveness and tolerability in 64 paediatric patients with refractory epilepsies. Epileptic Disord 2011;13:382-8
  5. Colicchio G, Policicchio D, Barbati G, et al. Vagal nerve stimulation for drug-resistant epilepsies in different age, aetiology and duration. Childs Nerv Syst 2010;26:811-9
  6. Shahwan A, Bailey C, Maxiner W, Harvey AS. Vagus nerve stimulation for refractory epilepsy in children: More to VNS than seizure frequency reduction. Epilepsia 2009;50:1220-8
  7. Elliott RE, Rodgers SD, Bassani L, et al. Vagus nerve stimulation for children with treatment-resistant epilepsy: a consecutive series of 141 cases. J Neurosurg Pediatr 2011;7:491-500
  8. Frost M, Gates J, Helmers SL, et al. Vagus nerve stimulation in children with refractory seizures associated with LennoxGastaut syndrome. Epilepsia 2001;42:1148-52
  9. Aldenkamp AP, Majoie HJ, Berfelo MW, et al. Long-term effects of 24-month treatment with vagus nerve stimulation on behaviour in children with Lennox-Gastaut syndrome. Epilepsy Behav 2002;3:475-9
  10. Cersósimo RO, Bartuluchi M, De Los Santos C, Bonvehi I, Pomata H, Caraballo RH. Vagus nerve stimulation: effectiveness and tolerability in patients with epileptic encephalopathies. Childs Nerv Syst 2011;27:787-92
  11. McLachlan RS, Sadler M, Pillay N, et al. Quality of life after vagus nerve stimulation for intractable epilepsy: is seizure control the only contributing factor? Eur Neurol 2003;50:16- 9
  12. Majoie HJ, Berfelo MW, Aldenkamp AP, Renier WO, Kessels AG. Vagus nerve stimulation in patients with catastrophic childhood epilepsy, a 2-year follow-up study. Seizure 2005;14:10-8
  13. Mikati MA, Ataya NF, El-Ferezli JC, et al. Quality of life after vagal nerve stimulator insertion. Epileptic Disord 2009;11:67-74
  14. Klinkenberg S, van den Borne CJ, Aalbers MW, et al. The effects of vagus nerve stimulat